Cardiovascular Biochemistry

Main lines of research

Atherosclerosis mechanisms

  • Analysis of apolipoprotein J (apoJ) as a marker of CVR.
  • Use of mimetic peptides derived from apoJ as therapeutic tools.
  • Involvement of LDL(-) on lipid accumulation in cardiomyocytes and heart failure.

Inflammatory mechanisms induced by LDL(-) on monocytes from patients with diabetes.

  • Diagnosis of chronic or acute cardiovascular diseases.
  • Development of algorithms for ruling-out acute coronary disease.
  • Assessment of new biomarkers of acute cardiovascular disease: cardiac troponins, natriuretic peptides, ST-2.
  • Development of methods for point-ofcare biomarker measurement.
  • Vulnerability markers in atheromatous plaque: electronegative LDL, LDL size, HDL function, myeloperoxidase, phospholipase.


  • Determine the intracellular mechanisms involved in the inflammatory response induced by LDL(-) and the components of the particle that entail atherogenicity.
  • Analyse the therapeutic potential of mimetic peptides derived from apo J to delay the development of atherosclerosis in animal models.
  • Demonstrate that electronegative LDL is a marker of vulnerable atheromatous plaque.
  • Find new markers of cardiovascular risk in diseases such as diabetes, HIV or cardiac failure.
This site is registered on as a development site.

Aquest lloc web utilitza cookies per millorar l'experiència de navegació i realitzar tasques analítiques. Si continues navegant, considerem que n’acceptes l’ús. Més informació